Appears on
Articles2
AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B
Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR mutations. The post AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B appeared first on GEN - Genetic Engineering and Biotechnology News .
0
GEN2d agoStockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III
Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast for the first half of 2026, driven by its series of partnerships and a wide-ranging pipeline whose first program has reached late-stage development this past we
0
GEN4d ago